Literature DB >> 19542776

Lansoprazole, ranitidine, and metoclopramide: comparison of practice patterns at 4 level III NICUs within one healthcare system.

Cindy K Barney1, Vickie L Baer, Scott H Scoffield, Diane K Lambert, Mike Cook, Robert D Christensen.   

Abstract

PURPOSE: Evidence is needed to guide NICU use of lansoprazole (Prevacid), ranitidine (Zantac), and metoclopramide (Reglan). As a step toward that goal, we conducted a historic cohort analysis of all patients who received any of these medications in 4 Intermountain Healthcare NICUs during the year 2006.
SUBJECTS: Data were obtained from all patients admitted between January 1 and December 31, 2006, to any of 4 Intermountain Healthcare NICUs.
DESIGN: This was a retrospective descriptive design.
METHODS: Data were obtained from electronic pharmacy records and electronic medical records. The NICUs involved were blinded and included McKay-Dee Hospital Center, Ogden, Utah; LDS Hospital, Salt Lake City, Utah; Utah Valley Regional Medical Center, Provo, Utah; and Dixie Regional Medical Center, St George, Utah.
RESULTS: Although the demographics of the patients at the 4 centers were similar, significant differences were seen among the centers in drug use patterns. Lansoprazole use ranged from a high of 17% of patients in one center to a low of 7% of patients in another. Ranitidine use ranged from 9% in one center to 1% in another. Metoclopramide use ranged from 9% of patients in one center to <1% in another.
CONCLUSIONS: The extreme variability among the centers in use patterns of these 3 medications suggests lack of an adequate evidence base to guide practice and indicates that case controlled studies or random controlled trials are needed to devise a consistent evidence-based approach.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542776     DOI: 10.1097/ANC.0b013e3181a88358

Source DB:  PubMed          Journal:  Adv Neonatal Care        ISSN: 1536-0903            Impact factor:   1.968


  5 in total

1.  Significance of gastroesophageal refluxate in relation to physical, chemical, and spatiotemporal characteristics in symptomatic intensive care unit neonates.

Authors:  Sudarshan R Jadcherla; Juan Peng; Chin Yee Chan; Rebecca Moore; Lai Wei; Soledad Fernandez; Carlo DI Lorenzo
Journal:  Pediatr Res       Date:  2011-08       Impact factor: 3.756

2.  Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease.

Authors:  Jaroslaw Kierkus; Wanda Furmaga-Jablonska; Janice E Sullivan; Elmer S David; Dan L Stewart; Natalie Rath; Caifeng Fu; Wenjin Wang; Mary K Maguire; Gail M Comer
Journal:  Dig Dis Sci       Date:  2010-07-07       Impact factor: 3.199

3.  Use of Gastroesophageal Reflux Medications in Premature Infants After NICU Discharge.

Authors:  Jo Ann D'Agostino; Molly Passarella; Ashley E Martin; Scott A Lorch
Journal:  Pediatrics       Date:  2016-12       Impact factor: 7.124

4.  Use of ranitidine is associated with infections in newborns hospitalized in a neonatal intensive care unit: a cohort study.

Authors:  Ruth N S Santana; Victor S Santos; Ruy F Ribeiro-Júnior; Marina S Freire; Maria A S Menezes; Rosana Cipolotti; Ricardo Q Gurgel
Journal:  BMC Infect Dis       Date:  2017-05-30       Impact factor: 3.090

5.  Association between histamine-2 receptor antagonists and adverse outcomes in neonates: A systematic review and meta-analysis.

Authors:  Victor S Santos; Marina S Freire; Ruth N S Santana; Paulo R S Martins-Filho; Luis E Cuevas; Ricardo Q Gurgel
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.